← 홈

Antibody · 고형암 (전체)

287개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 287개
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab, Etoposide, Carboplatin, Tarlatamab)

Small Cell Carcinoma of Lung · Small Cell Carcinoma of Lung

#SmallCellCarcinomaofLung#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 RECRUITING
AntibodystaleAmgenPhase 2

Bemarituzumab (Bemarituzumab)

Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 46.8%임상시험 2상태 ACTIVE
AntibodystaleEli LillyPhase 2

CDX-3379 and cetuximab (CDX-3379 and cetuximab)

Advanced Head and Neck Squamous Cell Carcinoma · Advanced Head and Neck Squamous Cell Car

#AdvancedHeadandNeckSquamousCellC#Antibody#Phase2#항체#면역항체+2
효능 ORR 7%임상시험 2상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Coformulated vibostolimab/pembrolizumab)

Metastatic Urothelial Carcinoma; Urothelial Neoplasms · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 RECRUITING
AntibodystaleMacroGenicsPhase 3

Enoblituzumab (Enoblituzumab)

Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase3#항체#면역항체+3
효능 ORR 6%임상시험 2상태 DISCONTINUED
AntibodystaleQilu Pharmaceutical Co., Ltd.Phase 2

QL1706 (Iparomlimab and Tuvonralimab Injection, Iparomlimab and Tuvonralimab Injection (QL1706))

Hepatocellular Carcinoma (HCC); Immunotherapy · Hepatecellular Carcinoma

#HepatecellularCarcinoma#Antibody#Phase2#항체#면역항체+4
임상시험 2상태 RECRUITING
AntibodystaleMerck KGaAPhase 1

Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab (Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#Antibody#Phase1#항체#면역항체+2
임상시험 2상태 ACTIVE
AntibodystaleMargaret Gatti-MaysPhase 2

Naxitamab (Naxitamab)

Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 2상태 RECRUITING
AntibodystaleRoswell Park Cancer InstitutePhase 1

Nimotuzumab (Nimotuzumab)

EGFR Gene Mutation; Recurrent Non-Small Cell Lung Carcinoma · Advanced Cancer

#AdvancedCancer#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Niraparib + Nivolumab)

Pancreatic Adenocarcinoma · Pancreatic Adenocarcinoma

#PancreaticAdenocarcinoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 7.7%임상시험 2상태 ACTIVE
AntibodystaleBeiGenePhase 3

Ociperlimab (Ociperlimab)

Advanced Hepatocellular Carcinoma · FRα

#FR#Antibody#Phase3#항체#면역항체+3
효능 ORR 100%임상시험 2상태 DISCONTINUED
AntibodyBiologicstaleShanghai Kechow Pharma, Inc.Phase 2

Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)

Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 RECRUITING
AntibodystaleXencor, Inc.Phase 2

XmAb18087 (XmAb18087)

Merkel Cell Carcinoma; Small Cell Lung Cancer · Merkel Cell Carcinoma

#MerkelCellCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 DISCONTINUED
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, YL201 and atezolizumab)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 RECRUITING
AntibodystaleRadboud University Medical Cent…Preclinical

111Indium-bevacizumab (111Indium-bevacizumab)

Clear Cell Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma

#ClearCellRenalCellCarcinoma#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAgenus Inc.Phase 1

AGEN1223 and balstilimab (AGEN1223 and balstilimab)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleJeffrey ClarkePhase 1

AMG 479, Everolimus, Panitumumab (AMG 479, Everolimus, Panitumumab)

Advanced Solid Tumors, Non-small Cell Lung Cancer · Advanced Solid Tumors, Non-small Cell Lu

#AdvancedSolidTumorsNon-smallCell#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, AMVAC + Nivolumab)

Muscle-Invasive Bladder Carcinoma · Muscle-Invasive Bladder Carcinoma

#Muscle-InvasiveBladderCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystalePeking Union Medical CollegePhase 2

trastuzumab (Herceptin, AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAntengene Therapeutics LimitedPhase 1

nivolumab (Opdivo, ATG-017+Nivolumab)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED

5 / 15 페이지

← 이전다음 →